New York and Bangkok (PRWEB) July 11, 2006
Following the death of his 23 year old son, Joshua, Jim Goldberg of New York, returned to Bangkok Thailand to formally join the Royal Thai Police investigation as a co-complaint, and has named 10 persons at Bumrungrad Hospital (BH) as persons who are allegedly responsible for negligence leading to his son’s demise.
The charges Mr. Goldberg is bringing name various executives of the hospital, all Americans and former employees of Tenet Hospital/National Medical Enterprises. Additionally 7 doctors who were directly involved in the care of his son have also been named.
Additional persons may be included in the complaint as the investigation and interrogation of various individuals continues. The Royal Thai Police will be submitting their findings and recommendations to the Public Prosecutor who will determine whether there is sufficient cause to bring a court action against some or all of the named individuals.
Under Thai law, Mr. Goldberg, may elect to bring private criminal charges either in addition to those which the Thai government may elect to pursue. Mr. Goldberg has stated that it is highly likely that he will prefer private charges but is awaiting the outcome of the police investigation.
Bumrungrad Hospital was owned, in part by Tenet Healthcare, a US based hospital corporation, until 1996 when they divested their remaining 40% interest in Bumrungrad, a self proclaimed leader in the fast emerging arena of Medical Tourism.
A careful examination of SEC filings of Tenet Healthcare, reveals that in 2001 and 2002, Tenet claimed that Bumrungrad was a wholly owned subsidiary of that corporation. However, Bumrungrad Hospital, in it’s filings with the Thai Securities Exchange, makes no such statement that they were owned by Tenet Healthcare. These discrepancies are being investigated. Tenet is traded on the NYSE and Bumrungrad Hospital on the Thai Stock Exchange. See: http://www.sec.gov/Archives/edgar/data/70318/000091205701529717/a2056090zex-21.htm
Subsequent SEC filings of Tenet with the SEC indicate that, subsequent to 2003, that they no longer claim that Bumrungrad is or was a wholly owned subsidiary and no mention of a sale or divestiture of Bumrungrad has been located in any SEC filings.
A call to the Investor Relations office of Tenet made by Mr. Goldberg in late May, 2006, received a telephone response that Tenet has no relationship whatsoever with Bumrungrad Hospital.
The untimely death of Mr. Goldberg’s 23 year old son is detailed on a password protected website, http://www.bumrungraddeath.com This website captures the actual correspondence between Bumrungrad Hospital, which is accredited by the US based not for profit corporation, the Joint Commission on the Accreditation of Hospitals, and Mr. Goldberg. Additionally, Mr. Goldberg’s correspondence with the Joint Commission is also captured on the site along with numerous medical records, forensic reports and other details relating to the death of his son while a patient at Bumrungrad between 12 Feb 2006 and 24 Feb 2006.
The Royal Thai police were alerted about the death of Joshua Nathaniel Goldberg at Bumrungrad Hospital by an anonymous caller. This call triggered the beginning of a police investigation and the seizure of Joshua Goldberg’s body which was transported to a government Forensic Institute for post mortem analysis.
Mr. Goldberg has publicly stated that it is his intention “to leave no stone unturned” in obtaining absolute clarity about the causes of his son’s death and to determine who was responsible.
Joshua Goldberg was admitted for the treatment of a swollen left leg and the loss of feeling and motion in that leg. On the day of his death, Joshua had been administered 20 drugs by Bumrungrad hospital, at least 6 of which are known by the PDR (Physicians Desk Reference) to be contraindicated (causing adverse reactions). Some of the drugs administered to Joshua Goldberg were drugs to which he was known to have been allergic.
The Thai Forensic Institute is soon to release a completed autopsy report.
This information is not for USE or PUBLICATION or DISTRIBUTION in Thailand.
# # #